Tag: biolojic

[Biolojic in Haaretz] From Israeli Lab: First AI-designed Antibody Enters Clinical Trials

Aulos Biosciences is now recruiting cancer patients in Australian medical centers for a trial of the world’s first antibody drug designed by a computer. The computationally designed antibody, known as AU-007, was planned by the artificial intelligence platform of Israeli biotech company Biolojic Design from Rehovot, in a way that would target a protein in the human body known as interleukin-2 (IL-2). Read...

Read More

[Biolojic in Yahoo] Aulos Bioscience Announces Preclinical Data Demonstrating Ability of Novel IL-2 Therapeutic AU-007 to Eliminate Solid Tumors

LARKSPUR, Calif., March 21, 2022–(BUSINESS WIRE)–Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, has shared new preclinical data demonstrating solid tumor elimination when dosing AU-007, a monoclonal antibody computationally designed by Biolojic Design. Data were presented at a recent antibody biology and engineering conference. Read...

Read More

[Biolojic in Business Wire] Aulos Bioscience receives HREC approval to initiate first-in-human clinical trial evaluating anti-tumor activity of novel IL-2 therapeutic AU-007

LARKSPUR, Calif.–(BUSINESS WIRE)–Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced that it has obtained approval from the Monash Health Human Research Ethics Committee (HREC) to initiate a Phase 1/2, first-in-human trial of AU-007, a monoclonal antibody computationally designed by Biolojic Design. AU-007 leverages a highly differentiated approach to harnessing the power of interleukin-2 (IL-2) to eradicate solid tumors. Read...

Read More
  • 1
  • 2

Latest from Twitter